OT mobile menu

Search form


Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

The novel immunotherapy combination of epacadostat plus pembrolizumab shows promising clinical activity in advanced melanoma patients.

Genetic mutation analysis confirms the malignant potential of intermediate skin lesions that are neither benign moles nor yet melanomas.

Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases.

Nivolumab alone or in combination with ipilimumab are promising treatment options for patients with mucosal melanoma, according to a new study.

The FDA has approved the MEK inhibitor cobimetinib in combination with the BRAF inhibitor vemurafenib for the treatment of advanced metastatic or unresectable BRAF-mutated melanoma.

Ipilimumab (Yervoy, Bristol Myers Squibb) is now approved by the Food and Drug Administration (FDA) as an adjuvant therapy for stage III melanoma patients.

The FDA has approved its first oncolytic virus therapy talimogene laherparepvec (Imlygic), a drug for the treatment of patients with melanoma lesions in the skin and lymph nodes.


Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.